Antibody-targeted nanoparticles for cancer therapy

Francois Fay, Christopher Scott

Research output: Contribution to journalArticle

106 Citations (Scopus)


In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, in particular antibodies. Antibody-nanoparticle conjugates have the potential to elicit effective targeting and release of therapeutic targets at the disease site, while minimizing off-target side effects caused by dosing of normal tissues. This article provides an overview of various antibody-conjugated nanoparticle strategies, focusing on the rationale of cell-surface receptors targeted and their potential clinical application.
Original languageEnglish
Pages (from-to)381-394
Number of pages14
Issue number3
Publication statusPublished - Mar 2011


Cite this